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Summary (239 words): Despite the availability of more than 15 new “antiepileptic drugs”, 
the proportion of pharmacoresistant epilepsy patients has remained constant at about 20-
30%. Furthermore, no disease-modifying treatments shown to prevent the development of 
epilepsy following an initial precipitating brain injury or to reverse established epilepsy have 
been identified to date. This is likely in part due to the polyetiologic nature of epilepsy, which 
in turn requires personalized medicine approaches. Recent advances in imaging, pathology, 
genetics and epigenetics have led to new pathophysiological concepts and the identification 
of monogenic causes of epilepsy. In the context of these advances, the First International 
Symposium on Personalized Translational Epilepsy Research (1st ISymPTER) was held in 
Frankfurt on September 8th 2016 to discuss novel approaches and future perspectives for 
personalized translational research. These included new developments and ideas in a range 
of experimental and clinical areas such as deep phenotyping, quantitative brain imaging, 
EEG/MEG-based analysis of network dysfunction, tissue based translational studies, innate 
immunity mechanisms, mircoRNA as treatment targets, functional characterization of genetic 
variants in human cell models and rodent organotypic slice cultures, personalized treatment 
approaches for monogenic epilepsies, blood-brain-barrier dysfunction, therapeutic focal 
tissue modification, computational modeling for target and biomarker identification, and cost 
analysis in (monogenic) disease and its treatment. This report on the meeting proceedings is 
aimed at stimulating much needed investments of time and resources in personalized 
translational epilepsy research. This Part I includes the clinical phenotyping and diagnostic 
methods, EEG network-analysis, biomarkers and personalized treatment approaches. In Part 
II experimental and translational approaches will be discussed [1]. 
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Introduction: Epilepsy affects over 50 million people worldwide and is thus one of the 
commonest chronic neurological conditions. It is characterized not only by recurrent seizures, 
but also by a 2-3-fold increase in mortality, stigma, psychobehavioral comorbidity, and 
decreased social participation and quality of life (QoL) [2]. Epilepsy is an heterogeneous 
group of conditions caused by many different underlying etiologies ranging from monogenic 
mutations to acquired focal lesions [3]. About one third of patients are refractory to current 
medical treatment which is mainly directed at the suppression of epileptic seizures by 
globally decreasing neuronal excitability, but not at comorbidities or the underlying 
neurobiology [4]. At the moment we are not able to prevent epileptogenesis (the 
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development of epilepsy following an initial precipitating injury such as a febrile seizure or 
traumatic brain injury) and there are very few disease modifying treatments [5].  
Personalized medicine in epilepsy is currently restricted to pharmacorefractory patients with 
focal (mostly lesional) epilepsy syndromes who are candidates for epilepsy surgery [6]. The 
considerable progress in neuroimaging during the past decades and the increased utilization 
of invasive EEG, mainly stereo-EEG (s-EEG) allows the localization of the individual 
epileptogenic zone and its removal, destruction or disconnection by microsurgery and 
stereotactic ablation in a small, but growing number of, patients, resulting in decreased 
mortality and increases in social participation and QoL [7], [8]. Epilepsy surgery also provides 
access to viable epileptogenic tissue allowing unique insights in the neurobiology and 
pathophysiology of epilepsy, including the detection of epileptogenic somatic mutations [9], 
[10], [8], [11]. 
Currently a second revolution in diagnosis is evolving rapidly - the detection of pathogenic 
gene variants in an increasing number of patients affected by epileptic seizures and 
encephalopathy starting during the first 2 years of life (“epileptic encephalopathies”) 
[12,12,13]. The identification of causative genetic variants has given us insights into the 
molecular pathophysiology of epilepsy (and encephalopathies) and has facilitated the 
identification of molecular targets for personalized treatments in affected individuals that 
could potentially be used in larger patient groups. There are already examples of successful 
treatments directed at individual molecular mechanisms such as the use of the ketogenic diet 
in patients with mutations of glucose transporter genes, or the repurposing of approved drugs 
to treat, for instance, gain of function mutations in ion channels [13].  
These recent developments open new avenues to personalized translational epilepsy 
research. In a broader context, translational medicine has been defined by the European 
Society for Translational Medicine (EUSTM) as an ‘interdisciplinary branch of the biomedical 
field supported by three main pillars: benchside, bedside and community’ [14]. Major goals of 
translational research are given by the promotion of improvement in prevention, diagnosis, 
and therapies based on highly collaborative "bench-to-bedside" approaches [15][16].  
Based on the “1st International Symposium on Personalized Translational Epilepsy 
Research” held in Frankfurt in September 2016 we explore here several approaches to 
personalized translational epilepsy research.   
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Comprehensive deep phenotyping as a prerequisite for personalized medicine  
Personalized medicine is based on precise phenotyping that allows the identification of well-
defined groups of patients that are amenable to specific treatment approaches. The 
recognition of relevant and treatable factors in these groups allows the development of 
tailored therapeutic approaches. Even with the advent of whole genome screening, the 
complexity of the interaction between genetic, environmental and stoachastic processes 
means that deep phenotyping still plays a critical role [17]. Such a comprehensive approach 
encompasses different levels of information ranging from clinical features up to tissue 
functions, metabolites, protein and cell function-pathways as well as regulatory processes 
including the role of mRNA [17]. As a consequence, all available evaluation methods 
including patient’s history, clinical examination, neuropsychological tests, imaging 
techniques, laboratory data as well as electrophysiological and functional tests are suitable 
tools during the phenotyping process. This approach is expensive, time and resource 
consuming and data processing and interpretation are challenging. Additionally, time and 
developmental dependence of the underlying pathophysiological conditions during the 
process of epileptogenesis are notable pitfalls in this process. As deep phenotyping 
comprises a huge amount of data, sufficient integration of different datasets is important [18]. 
A database like the Human Phenotype Ontology project (HPO) combined standardized 
descriptions of data with a branch tree for ranking the obtained information [19], [18]. In both 
studies, this allowed the linking of apparently different conditions by similar features and the 
identification of new correlations between the underlying genetic condition and the 
phenotypic features. The “cross-disorder” relevance of several symptoms can thereby be 
established and top-down as well as bottom-up approaches can be realized. However, this 
promising advance represents only a first step as the included epilepsy terms in this 
database are insufficient to provide a phenotypic description on the level required for deep 
phenotyping. The more detailed characterization on each level of information and its 
standardization will help to develop further computational disease models of epilepsy and 
extensive analysis of these data. 
 
Quantitative MRI techniques to define epileptogenic lesions  
Malformations of cortical development (MCD) including focal cortical dysplasia (FCD), 
periventricular nodular heterotopia and polymicrogyria are common causes of refractory 
epilepsy, and their detection is crucial for successful epileptic surgery [3]. FCD is often 
characterized by hypo-, de-, or dysmyelination in the subcortical white matter, changes that 
cause blurring of the gray-white matter junction and mimic increased cortical thickness in T2- 
and T1-weighted magnetic resonance (MR) images. These changes are often subtle and 
hard to identify by visual evaluation of data acquired with conventional MR sequences. It is 
particularly difficult to define the margin between normal and pathological brain with current 
techniques. Furthermore, cortex overlying and adjacent to nodular periventricular heterotopia 
has been shown to be epileptogenic but usually looks normal on conventional MRI [20]. One 
promising novel approach to improve the detection and delineation of pathological tissue in 
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patients with MCD is the acquisition of quantitative MRI (qMRI) maps in patients with MCD, 
optimizing contrast characteristics for instance of the gray-white matter junction. 
In contrast to conventional MR techniques which are based on the acquisition of data with 
different contrast weighting, the goal of qMRI is the mapping of specific tissue parameters, 
such as the relaxation times (T1, T2, T2*) and the proton density (PD). The advantage is that 
these maps provide exclusive information about the respective parameter of interest and are 
not biased by any other parameter. This allows for the detection of microstructural 
pathologies that might go unnoticed in conventional MR images. Furthermore, as the 
parameter maps provide “pure” contrasts, they can be used to create synthetic MR data with 
improved contrast characteristics. The BIC in Frankfurt/Main provides a series of qMRI 
techniques that have been applied in several previous studies, such as the investigation of 
patients with multiple sclerosis [21], glioblastoma [22], Parkinson's disease [23], and stroke 
[24]. 
 
Assessing network dysfunction in epilepsy  
Network dysfunction in epilepsy has recently received a lot of attention because 
Neuroscience, in general, has moved from focal to more dynamic approaches that reveal 
temporal patterns in distributed neural representations; such spatially and temporally 
distributed networks are also likely to contribute to the development of epileptic seizures. 
One of the major challenges in defining functional anomalies in epilepsy is the heterogeneity 
of disease manifestations.  
The changes that occur in neural networks have been investigated by numerous functional 
imaging experiments that have compared interictal resting state networks in epilepsy patients 
with ones observed in healthy controls using fMRI. Both hyper- and hypoconnected brain 
networks have been documented, suggesting either prominent patient heterogeneity or the 
fact that the BOLD response may blur temporal dynamics that are necessary for detection of 
epilepsy-related changes.  
Interictal combined EEG/MEG recordings represent a promising experimental approach that 
offers optimal temporal and spatial resolution. Using this methodology, Englot and 
colleagues documented that the putative epileptogenic zone has increased imaginary 
coherence with the rest of the brain [25], and that this measure correlated well with seizure 
freedom upon resection of this area.  
While this measure is still relatively coarse and the physiological meaning of global 
connectivity remains obscure, a more refined analysis of epileptogenic networks can be 
performed on ictal data. Using intracranial EEG from invasive recordings, Bartolomei and 
colleagues proposed an epileptogenicity index that takes the onset of high frequency 
oscillations in the acquired data into account [26]. While the number of areas with higher 
epileptogenicity index increases with the duration of epilepsy, the clinical relevance of this 
measure for surgery outcome has not yet been confirmed [27].  
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Disappointingly, other research on epileptic networks using graph theoretical descriptors of 
interictal functional networks [28,29] or functional connectivity measures based on direct 
electrical stimulation [10] have not yet been shown to reliably predict surgical outcomes. 
A novel approach will be the study of information theoretic measures in focal epilepsy. 
Invasive and non-invasive recordings of patients with focal, particularly temporal lobe 
epilepsy can be used to investigate the effects of antiepileptic drugs on these measures. 
Furthermore, based on these measures the relationship between information theoretic 
measures in neural recordings with the individual phenomenology can be studied. The 
rationale behind this approach is the assumption that information processing will be reduced 
in epileptic networks and that the identification of reliable measures could help in defining the 
individual epileptogenic zone and explain neuropsychological findings. Such an approach of 
personalized diagnostics differs substantially from previous group analyses. 
 
Large scale networks underlying cognitive functions revealed by s-EEG in epilepsy 
patients  
The field of cognitive neuroscience concerns itself with how cognitive abilities arise from 
brain activity. Language and music are just two examples of cognitive systems that have 
been and continue to be the subject of considerable research.  However, they demonstrate 
clearly the highly distributed nature of information processing in the brain. Specifically, 
functional imaging methods have revealed that both language and music processing involve 
not just auditory cortices but also several medial temporal as well as frontal regions [30], [31], 
[32]. With regard to possible mechanisms underlying the transfer of information within such 
distributed brain networks, oscillations are considered a highly likely candidate [33].  
Magneto-Electroencephalography, by offering a window into neural oscillatory activity has 
allowed the temporal dynamics of information transfer within the brain to be explored. 
However, stereotactic EEG recordings, in particular, give access to neural data at a 
combined spatial and temporal resolution that is not offered by such non-invasive methods. 
As a result, a growing research effort has taken advantage of s-EEG data to explore the 
neural substrates and mechanisms underlying different aspects of human cognition and 
affect. In our work, for instance, we have used s-EEG to show that oscillatory interactions 
(specifically in the theta and alpha band) between the auditory cortex, the amygdala and the 
orbitofrontal cortex, are modulated during music listening. Using a directed measure of 
connectivity (Granger causality) allowed us to further demonstrate that the strength of 
directed flow from the amygdala to the orbitofrontal cortex specifically, is highly predictive of 
the valence of the sound heard [34].  
Critically, studies such as ours may not only offer insights into how information processing is 
distributed across large-scale brain networks, but may also offer a deeper understanding of 
how epilepsy networks are organized for use in clinical applications. Novel methods that 
detect information coded in time (defined as information-carrying modulations of neural 
oscillations, [35]) provide additional insights compared to those focusing on spatially 
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distributed information. An ever- growing interest in revealing such neural temporal dynamics 
has led to a proliferation of several different methods for inferring functional connectivity [36]. 
While the use of these numerous methods has led to considerable insights regarding the 
distributed nature of information processing, one particular method, transfer entropy, seems 
to offer several additional advantages. First, being model free, it reduces the need for 
potentially inaccurate model assumptions. Secondly, it has the power to reveal both linear 
and nonlinear interactions allowing detailed analysis of directed interactions at different 
descriptive levels [37]. 
The use of methods like transfer entropy to provide in-depth knowledge of information 
transfer during different cognitive tasks offers the possibility to identify affected cognitive 
networks in individual patients. The tendency has been for clinicians to base their decision-
making on descriptive analysis of brain activity; advanced network and information theoretic 
measures will improve the precision of the description of ictal networks for highly 
personalized therapeutic treatment. 
 
The ketogenic diet as a treatment concept for epilepsy and underlying tumors  
The ketogenic diet has been investigated as treatment for epilepsy since the 1920s but only 
more recently have the first randomized clinical trials been reported [38]. For some rare 
syndromes, like GLUT1 deficiency syndrome, the primary mechanism of action of the 
ketogenic diet apparently consists in providing the brain with alternative energy sources. For 
most cases of intractable epilepsies, however, the anticonvulsant mechanisms are only 
partially understood and probably involve diverse mechanisms. Both the ketogenic diet as 
well as cyclic fasting lead to increasing levels of ketone bodies (3-hydroxybutyrate, 
acetoacetate) in the serum that can readily be used for energy production by cells with the 
appropriate enzymatic machinery, i.e., neurons. Due to glucose addiction of cancer cells, 
dietary interventions have also drawn great interest as a potential cancer treatment and 
promising in vitro data have been reported both of combinations with radio- and 
chemotherapy [39]. Currently, clinical trials to investigate cyclic fasting and ketogenic diets in 
brain tumors are underway (e.g. NCT01754350) [40]. How different dietary interventions 
affect metabolism of tumors or brain tissue in humans in vivo has not been closely monitored 
thus far and would be essential for a more in depth understanding of dietary interventions as 
a treatment concept for epilepsies and brain tumors. Microdialysis offers the opportunity of a 
dynamic measurement of metabolites in tissue. We aim to include patients with a suspected 
glioma and an indication for a brain biopsy in a study (ERGO 3) where a microdialysis 
catheter is placed in the biopsy canal. After a period of dietary interventions the lesion is 
resected and the catheter removed while the patient is still fasting. This will allow important 
insight into the metabolism of glioma and brain tissue during dietary interventions as well as 
a correlation of metabolic changes with MRI and histology data. 
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Personalized treatment approaches for monogenic epilepsies  
Currently available antiepileptic drugs (AED) reduce the likelihood of seizure occurrence but 
do not modify the underlying disease process. The genetic causes of a number of monogenic 
epilepsies have been discovered recently. Understanding the pathophysiological 
consequences of the identified mutations increasingly allows the initiation of therapies that 
modify the effect caused by the specific mutation (precision medicine). This approach often 
includes repurposing of already available drugs that are approved for the treatment of 
different diseases [13]. 
Current state of the art: The following precision medicine treatments are established and in 
routine clinical use: The classic ketogenic diet in GLUT1 deficiency syndrome bypasses the 
defective glucose transport across the blood-brain barrier. The modified Atkins diet, a less 
strict dietary regimen, has also been shown to be effective [41]. The mTOR inhibitor 
everolimus inhibits the overactive mTOR pathway in tuberous sclerosis [5]. Sodium channel 
blockers have been observed in clinical settings to be particularly effective in epileptic 
encephalopathy (EE) due to KCNQ2 and potentially SCN8A and SCN2A mutations. Sodium 
channel blockers can lead to worsening of SCN1A-positive Dravet syndrome. The AED 
stiripentol has been particularly effective in Dravet syndrome.  
Other treatments have been reported based on hypothetical considerations and have shown 
efficacy in a few case reports. These include the potassium channel opener retigabine in EE 
due to KCNQ2 loss-of-function mutations and the potassium channel blocker quinidine in EE 
due to KCNT1 gain-of-function mutations. Fenfluramine, which was developed as an appetite 
suppressant but withdrawn from the market due to serious adverse events, has shown 
outstanding efficacy in smaller case series of Dravet syndrome. 
Additional treatments are suggestive based on hypothetical considerations and/or efficacy in 
animal models but no or only single reports in patients are available. This includes the off-
label use of the mTOR inhibitor everolimus in patients with familial focal epilepsy with 
variable foci due to mutations in the GATOR1 complex (DEPDC5, NPRL2, NPRL3) leading 
to mTOR disinhibition, the NMDA receptor antagonist memantine in genetic focal epilepsies 
of childhood due to GRIN2A/2B mutations and the potassium channel blocker 4-
aminopyridine in patients with EE due to KCNA2 gain-of-function mutations. 
Future perspective: Large international efforts catalyzed by the ongoing progress in epilepsy 
genetics will produce extended cohorts of patients with similar mutations that will 
considerably advance the development of new precision medicine treatments. 
 
Assessment of cost-efficacy of personalized therapy  
Taking into account the high prevalence, the chronic course, associated utilization of health 
care resources and loss of productivity, epilepsy imposes a substantial burden on individuals, 
their caregivers and society as a whole [42]. Given the limited healthcare resources, it has 
become essential to gather reliable cost estimates as a scientific basis for resource allocation 
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and health policy decision making. This remains particularly important as the introduction of 
newer antiepileptic drugs, the use of generic medication, the marketing of brain stimulation 
devices, epilepsy surgery and the breakthrough of newer treatment options may cause a shift 
in the distribution of cost components resulting in an increase or decrease of total costs. 
However, costs should not be considered out of context, but must be related to treatment 
success and increase in QoL. Therefore close monitoring and prediction of the economic 
consequences of the introduction of new therapies into the market remains pivotal. These 
economic evaluations are particularly important in patients with intractable epilepsies as 
these are associated with high costs [43,44] While there is large evidence linking intractable 
epilepsies to a high resource allocation there is very little known about health economic 
consequences of more severe epilepsies, for example, associated with epileptic 
encephalopathies or specific syndromes such as TSC or Dravet syndrome (DS). A pilot study 
in DS demonstrated the high resource consumption driven by hospital treatment and 
emergency admissions in this severe childhood epilepsy [45]. The influence of an adjunctive 
therapy with stiripentol and clobazam on costs in refractory DS showed an increase in 
medication costs that was offset by reduction in hospitalization and emergency admissions 
[45]. Unfortunately this study did not evaluate indirect costs in terms of loss in the 
professional work of the parents due to the epileptic seizures or the quality of life in patients 
and caregivers, both important factors associated with wellbeing. Analysis of single patients 
showed that a decrease in costs and decrease in seizure frequency were not always 
correlated. This clearly demonstrated that treatment success does not depend upon a single 
outcome parameter such as seizure frequency. The overall impact of a new therapy on 
seizure frequency, seizure severity, cognitive improvement or side effects, and quality of life 
in patients and their caregivers has to be taken into account. Further studies are warranted to 
provide comprehensive data on the course of disease in epileptic encephalopathies or 
specific syndromes such as TSC or Dravet syndrome.  
 
Biomarkers of epilepsy and epileptogenesis  
Epilepsy is characterized by paroxysmal changes in neural dynamics, giving rise to short-
lived interictal discharges and epileptic seizures. As epileptic neural events propagate across 
specific, but possibly variable networks, the involved networks change their long-term activity 
due to neural plasticity. These structural and functional changes offer the opportunity to 
develop biomarkers aimed at detecting specific features of epilepsy and epileptogenesis [46]. 
A good biomarker should optimize the trade-off between the following requirements: 
sensitivity, specificity, predictive value, robustness and accessibility. While sensitivity and 
specificity are inherently competing concepts that influence the predictive value of a given 
biomarker, robustness and accessibility are determined by neurobiological and technological 
factors. In the context of clinical epileptology, EEG and MRI are currently the most widely 
used techniques, while other methods including molecular biomarkers measured in blood 
and cerebrospinal fluid (CSF) are increasingly evaluated. EEG biomarkers in daily routine 
involve the localization of interictal epileptiform discharges and seizure detection. On the 
other hand, automated approaches powered by recent advances in (un-)supervised feature 
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extraction and machine learning help to improve robustness and provide a means of 
reproducibly processing large data sets [47]. Moreover, they offer the chance to yield 
biomarkers not easily detected by the human observer. Important examples are EEG derived 
functional connectivity measures and the quantification of pathological high frequency 
oscillations associated with the epileptogenic zone. In particular, these methods can be used 
to characterize alterations of interictal brain function (see above). Structural MRI is related to 
the pathology underlying epilepsies and serves to localize and delineate epileptogenic 
lesions. With respect to imaging techniques, functional MRI approaches provide insight into 
metabolic changes and the activity of subcortical brain regions not accessible to EEG. The 
simultaneous recording of surface EEG and functional MRI has deepened our understanding 
of spike-related epileptic networks beyond basic spike localization [48]. Furthermore, given 
the wide variety of experimental designs available, functional connectivity during the interictal 
resting state and task-specific activations provide a multidimensional view on brain function 
in epilepsy and may help to bridge the gap with neuropsychological and behavioral 
biomarkers of epilepsy. One example of novel molecular biomarkers derived for body fluids 
are expression profiles of microRNA (miRNA) in plasma and CSF which are differentially 
regulated in epilepsy and also, importantly, in response to an epileptogenic insult (Raoof et al 
unpublished data). MiRNA have the advantage that they can be directly involved in the 
regulation of multiple pathways relevant to the neurobiology of epilepsy (Henshall et al. 
2016). If such biomarkers are sensitive, specific and have high positive predictive value, they 
may serve to detect subpopulations at high risk to develop epilepsy for inclusion in trials 
investigating antiepileptogenic interventions, for example in patients following head trauma or 
prolonged febrile seizures. In summary, designing biomarkers of epilepsy and 
epileptogenesis remains a challenging but promising goal in terms of information integration 
and translational clinical epileptology. 
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